FDG PET-CT in cervical cancer: Relationship between primary tumor FDG uptake and metastatic potential

Nuclear Medicine Communications

Volumn 31, Issue 6, 2010, Pages 526-531

  Yilmaz, Mustafa ^a   Adli, Mustafa ^a   Celen, Zeki ^a   Zincirkeser, Sabri ^a   Dirier, Ahmet ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

18F fluorodeoxyglucose; Cervical cancer; Maximum standardized uptake value; Positron emission tomography computed tomography; Standardized uptake value

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; PARAAORTIC LYMPH NODE; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; UTERINE CERVICAL NEOPLASMS;

EID: 77951769144     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32833800e7     Document Type: Article

References (26)

1. Gien LT, Covens A. Lymph node assessment in cervical cancer: prognostic and therapeutic implications. J Surg Oncol 2009; 99:242-247.
2. Grigsby PW, Singh AK, Siegel BA, Dehtashti F, Rader J, Zoberi I. Lymph node control in cervical cancer. Int J Radiation Oncol Biol Phys 2004; 59:706-712.
3. Singh AK, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical cancer. Int J Radiation Oncol Biol Phys 2003; 56:489-493.
4. Hopkins MP, Morley GW. Prognostic factors in advanced stage squamous cell cancer of the cervix. Cancer 1993; 72:2389-2393.
5. Stehman FB, Bundy BN, DiSaia PJ, Keys HM, Larson JE, Fowler WC. Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 1991; 67:2776-2785.
6. Basu S, Li G, Alavi A. PET and PET-CT imaging of gynecological malignancies: present role and future promise. Expert Rev Anticancer Ther 2009; 9:75-96.
7. Havrilesky LJ, Wong TZ, Secord AA, Berchuck A, Clarke-Pearson DL, Jones EL. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol 2003; 90:186-190.
8. Grigsby PW, Siegel BA, Dehtashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004; 22:2167-2171.
9. Xue F, Lin LL, Dehtashti F, Miller TR, Siegel BA, Grigsby PW. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol 2006; 101:147-151.
10. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 2007; 110:1738-1744.
11. Nambu A, Kato S, Sato Y, Okuwaki H, Nishikawa K, Saito A, et al. Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metastasis on FDG-PET. Ann Nucl Med 2009; 23:269-275.
12. Higashi K, Ito K, Hiramatsu Y, Ishikawa T, Sakuma T, Matsunari I, et al. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of multicenter study. J Nucl Med 2005; 46:267-273.
13. Li M, Liu N, Hu M, Shi F, Yuan S, Zhang P, et al. Relationship between primary tumor fluorodeoxyglucose uptake and nodal or distant metastases at presentation in T1 stage non-small cell lung cancer. Lung Cancer 2009; 63:383-386.
14. Kato H, Nakajima M, Sohda M, Tanaka N, Inose T, Miyazaki T, et al. The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer 2009; 115:3196-3203.
15. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006; 47:885-895.
16. Lucignani G, Paganelli G, Bombardieri E. The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. Nucl Med Commun 2004; 25:651-656.
17. Grigsby PW, Siegel BA, Dehtashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001; 19:3745-3749.
18. Takenaka T, Yano T, Ito K, Morodomi Y, Miura N, Kawano D, et al. Biological significance of the maximum standardized uptake values on positron emission tomography in non-small cell lung cancer. J Surg Oncol 2009; 100:688-692.
19. Han B, Lin S, Yu L, Wang R, Wang Y. Correlation of 18F-FDG PET activity with expressions of surviving, Ki67, and CD34 in non-small cell lung cancer. Nucl Med Commun 2009; 30:831-837.
20. Ho KC, Lin G,Wang JJ, Lai CH, Chang CJ, Yen TC. Correlation of apparent diffusion coefficients measured by 3 T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical tumor. Eur J Nucl Med Mol Imaging 2009; 36:200-208.
21. Mittra E, El-Maghraby T, Rodriguez CA, Quon A, McDougall IR, Gambhir SS, et al. Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging 2009; 36:1952-1959.
22. Hallett WA. Quantification in clinical fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2004; 25:647-650.
23. Akhurst T, Kates TJ, Mazumdar M, Yeung H, Riedel ER, Burt BM, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005; 23:8713-8716.
24. Yen TC, Ng KK, Ma SY, Chou HH, Tsai CS, Hsueh S, et al. Value of dualphase 2-fluoro-2-deoxy-D-glucose positron emission tomography in cervical cancer. J Clin Oncol 2003; 21:3651-3658.
25. Ma SY, See LC, Lai CH, Chou HH, Tsai CS, Ng KK, et al. Delayed 18F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 2003; 44:1775-1783.
26. Kostakoglu L, Agress H, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. RadioGraphics 2003; 23:315-340.